Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors

Vânia M A Moreira; Tadas S Vasaitis; Vincent C O Njar; Jorge A R Salvador

doi:10.1016/j.steroids.2007.08.004

Synthesis and evaluation of novel 17-indazole androstene derivatives designed as CYP17 inhibitors

Steroids. 2007 Dec;72(14):939-48. doi: 10.1016/j.steroids.2007.08.004. Epub 2007 Aug 15.

Authors

Vânia M A Moreira¹, Tadas S Vasaitis, Vincent C O Njar, Jorge A R Salvador

Affiliation

¹ Laboratório de Química Farmacêutica, Faculdade de Farmácia, Universidade de Coimbra, Rua do Norte, 3000-295, Coimbra, Portugal.

PMID: 17884122
DOI: 10.1016/j.steroids.2007.08.004

Abstract

A series of novel 1H- and 2H-indazole derivatives of the commercially available dehydroepiandrosterone acetate have been synthesized and tested for inhibition of human cytochrome 17alpha-hydroxylase-C(17,20)-lyase (CYP17), androgen receptor (AR) binding affinity, and cytotoxic potential against three prostate cancer (PC) cell lines.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Binding, Competitive / drug effects
Cell Line, Tumor
Cell Proliferation / drug effects
Dehydroepiandrosterone / analogs & derivatives*
Dehydroepiandrosterone / chemical synthesis*
Dehydroepiandrosterone / chemistry
Dehydroepiandrosterone / pharmacology*
Dehydroepiandrosterone / toxicity
Humans
Male
Prostatic Neoplasms / enzymology
Prostatic Neoplasms / pathology
Receptors, Androgen / metabolism
Steroid 17-alpha-Hydroxylase / antagonists & inhibitors*
Steroid 17-alpha-Hydroxylase / metabolism

Substances

Receptors, Androgen
Dehydroepiandrosterone
dehydroepiandrosterone acetate
Steroid 17-alpha-Hydroxylase